Advertisement

Der Nervenarzt

, Volume 88, Issue 12, pp 1428–1434 | Cite as

Neues zur symptomatischen MS‑Therapie: Teil 2 – Gangstörung und Spastik

  • T. HenzeEmail author
  • W. Feneberg
  • P. Flachenecker
  • D. Seidel
  • H. Albrecht
  • M. Starck
  • S. G. Meuth
Aktuelles

Zusammenfassung

Die symptomatische Behandlung der multiplen Sklerose (MS) hat heutzutage neben der Immuntherapie einen hohen Stellenwert im umfassenden Therapiekonzept dieser chronischen Erkrankung, trägt sie doch erheblich zu einer Verringerung von Beeinträchtigungen im Alltag, sozialen und beruflichen Leben sowie zur Verbesserung der Lebensqualität bei. Seit der letzten umfassenden Bestandsaufnahme 2004 in dieser Zeitschrift sowie den Leitlinien der Deutschen Gesellschaft für Neurologie/Klinisches Kompetenznetz Multiple Sklerose (DGN/KKN‑MS) zu Diagnose und Therapie der MS 2014 haben sich Neuerungen und Ergänzungen in den Bereichen Mobilität, Blasenfunktion, Sexualfunktionen, Augen, Fatigue, Kognition und Rehabilitation ergeben. Diese sowie weitere Aspekte (Messmethoden des jeweiligen Symptoms, Therapieziele, Gesamtbehandlungsplan) werden in einer Reihe aus 6 Einzelbeiträgen vorgestellt. Hier soll auf die Symptomatik von Gangstörung und Spastik eingegangen werden.

Schlüsselwörter

Multiple Sklerose Symptomatische Therapie Übersichtsartikel Gangstörung  Spastik 

What is new in symptomatic MS treatment: Part 2—gait disorder and spasticity

Abstract

The symptomatic treatment of multiple sclerosis (MS) nowadays is of similar importance as immunotherapy within a comprehensive concept of therapy of this chronic disease, since it contributes considerably to the reduction of disabilities in activities of daily living as well as social and occupational life. Moreover, symptomatic treatment is of great importance for amelioration of quality of life. Since our last survey of symptomatic MS treatment in 2004 and publication of the guidelines of the German Neurological Society and the Klinisches Kompetenznetz Multiple Sklerose (KKN‑MS) in 2014 several developments within the topics of mobility, bladder and sexual function, vision, fatigue, cognition and rehabilitation took place. These new findings together with further aspects of disease measures and overall treatment strategies of the respective symptoms, as well as treatment goals are introduced in a series of six individual contributions. Here, the symptoms of gait disorders and spasticity will be discussed.

Keywords

Multiple sclerosis Symptomatic therapy Review Gait disorder Spasticity 

Notes

Danksagung

Wir bedanken uns bei der Firma Almirall Hermal für finanzielle Hilfe bei der technischen Erstellung des Manuskripts, ebenso bei Frau Dr. U. Essner sowie Frau Dr. P. Hundehege und Frau L. Forster (Neurologische Universitätsklinik Münster) für ihre Hilfe bei der Erstellung des Manuskripts.

Einhaltung ethischer Richtlinien

Interessenkonflikt

T. Henze erhielt Vortragshonorare und Aufwandsentschädigungen für Advisory Boards von Almirall, Coloplast, Genzyme, Novartis, Sanofi. Interessenkonflikte bestehen nicht. W. Feneberg erhielt Vortragshonorare, Aufwandsentschädigungen für Advisory Boards bzw. Unterstützung bei Fortbildungen von Almirall, Bayer, Biogen Idec, Coloplast, Genzyme, Ipsen, Merz, Novartis, Sanofi-Aventis. Interessenkonflikte bestehen nicht. P. Flachenecker hat Honorare für Vorträge und Beratungstätigkeiten von den Firmen Almirall, Bayer, Biogen Idec, Genzyme, Novartis, Merck-Serono, Roche und Teva erhalten und an industriegesponsorten Studien von Biogen Idec und Novartis teilgenommen. Interessenkonflikte bestehen nicht. H. Albrecht hat Zahlungen für Reisekosten und/oder Fortbildungsveranstaltungen und/oder Studien erhalten von Almirall, Bayer Healthcare, Biogen Idec, Genzyme-Sanofi, Merck Serono, Teva. S.G. Meuth erhielt Vortragshonorare, Aufwandsentschädigungen für Advisory Boards bzw. Unterstützung bei Fortbildungen und/oder Projektförderung von Bayer, Bayer Schering, Biogen Idec, Genzyme, Merck Serono, Merck Sharp & Dohme, Novartis, Novo Nordisk, Sanofi-Aventis und Teva. D. Seidel und M. Starck geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Amatya B, Khan F, La Mantia L et al (2013) Non pharmacological interventions for spasticity in multiple sclerosis. Cochrane Database Syst Rev.  https://doi.org/10.1002/14651858.CD009974 Google Scholar
  2. 2.
    Fleuren JF, Voerman GE, Erren-Wolters CV et al (2010) Stop using the Ashworth Scale for the assessment of spasticity. J Neurol Neurosurg Psychiatry 81:46–52CrossRefPubMedGoogle Scholar
  3. 3.
    Henze T, von Mackensen S, Lehrieder G et al (2014) Linguistic and psychometric validation of the MSSS-88 questionnaire for patients with multiple sclerosis and spasticity in Germany. Health Qual Life Outcomes 12:119CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Patejdl R, Tesar S, Zettl UK (2014) Multiple sclerosis, neuromyelitis optica and spasticity: control of specific symptoms and quality of life. Fortschr Neurol Psychiatr 82:373–385CrossRefPubMedGoogle Scholar
  5. 5.
    Smania N, Picelli A, Munari D et al (2010) Rehabilitation procedures in the management of spasticity. Eur J Phys Rehabil Med 46:423–438PubMedGoogle Scholar
  6. 6.
    Bobath B (1985) Abnormal postural reflex activity caused by brain lesion. Lippincott Williams & Wilkins, PhiladelphiaGoogle Scholar
  7. 7.
    Henze T, Rieckmann P, Toyka KV (2004) Symptomatische Therapie der Multiplen Sklerose. Nervenarzt 75((Supp.1):2–39PubMedGoogle Scholar
  8. 8.
    Siev-Ner I, Gamus D, Lerner-Geva L et al (2003) Reflexology treatment relieves symptoms of multiple sclerosis: a randomized controlled study. Mult Scler 9:356–361CrossRefPubMedGoogle Scholar
  9. 9.
    Velikonja O, Curic K, Ozura A et al (2010) Influence of sports climbing and yoga on spasticity, cognitive function, mood and fatigue in patients with multiple sclerosis. Clin Neurol Neurosurg 112:597–601CrossRefPubMedGoogle Scholar
  10. 10.
    Ahmadi A, Arastoo AA, Nikbakht M et al (2013) Comparison of the effect of 8 weeks aerobic and yoga training on ambulatory function, fatigue and mood status in MS patients. Iran Red Crescent Med J 15:449–454CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Ghafari S, Ahmadi F, Nabavi M et al (2009) Effectiveness of applying progressive muscle relaxation technique on quality of life of patients with multiple sclerosis. J Clin Nurs 18:2171–2179CrossRefPubMedGoogle Scholar
  12. 12.
    Gunn H, Markevics S, Haas B et al (2015) Systematic review: the effectiveness of interventions to reduce falls and improve balance in adults with multiple sclerosis. Arch Phys Med Rehabil 96:1898–1912CrossRefPubMedGoogle Scholar
  13. 13.
    Pearson M, Dieberg G, Smart N (2015) Exercise as a therapy for improvement of walking ability in adults with multiple sclerosis: a meta-analysis. Arch Phys Med Rehabil 96:1339–1348CrossRefPubMedGoogle Scholar
  14. 14.
    Sosnoff JJ, Motl RW (2010) Effect of acute unloaded arm versus leg cycling exercise on the soleus H‑reflex in adults with multiple sclerosis. Neurosci Lett 479:307–311CrossRefPubMedGoogle Scholar
  15. 15.
    Giesser B, Beres-Jones J, Budovitch A et al (2007) Locomotor training using body weight support on a treadmill improves mobility in persons with multiple sclerosis: a pilot study. Mult Scler 13:224–231CrossRefPubMedGoogle Scholar
  16. 16.
    Rampello A, Franceschini M, Piepoli M et al (2007) Effect of aerobic training on walking capacity and maximal exercise tolerance in patients with multiple sclerosis: a randomized crossover controlled study. Phys Ther 87:545–555CrossRefPubMedGoogle Scholar
  17. 17.
    Coote S, Garrett M, Hogan N et al (2009) Getting the balance right: a randomised controlled trial of physiotherapy and exercise interventions for ambulatory people with multiple sclerosis. BMC Neurol 9:34CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Schyns F, Paul L, Finlay K et al (2009) Vibration therapy in multiple sclerosis: a pilot study exploring its effects on tone, muscle force, sensation and functional performance. Clin Rehabil 23:771–781CrossRefPubMedGoogle Scholar
  19. 19.
    Mori F, Codeca C, Kusayanagi H et al (2010) Effects of intermittent theta burst stimulation on spasticity in patients with multiple sclerosis. Eur J Neurol 17:295–300CrossRefPubMedGoogle Scholar
  20. 20.
    Miller L, Mattison P, Paul L et al (2007) The effects of transcutaneous electrical nerve stimulation (TENS) on spasticity in multiple sclerosis. Mult Scler 13:527–533CrossRefPubMedGoogle Scholar
  21. 21.
    van der Linden ML, Hooper JE, Cowan P et al (2014) Habitual functional electrical stimulation therapy improves gait kinematics and walking performance, but not patient-reported functional outcomes, of people with multiple sclerosis who present with foot-drop. PLOS ONE 9:e103368CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Otero-Romero S, Sastre-Garriga J, Comi G et al (2016) Pharmacological management of spasticity in multiple sclerosis: systematic review and consensus paper. Mult Scler 22:1386–1396CrossRefPubMedGoogle Scholar
  23. 23.
    Formica A, Verger K, Sol JM et al (2005) Gabapentin for spasticity: a randomized, double-blind, placebo-controlled trial. Med Clin (Barc) 124:81–85CrossRefGoogle Scholar
  24. 24.
    Collin C, Ehler E, Waberzinek G et al (2010) A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res 32:451–459CrossRefPubMedGoogle Scholar
  25. 25.
    Novotna A, Mares J, Ratcliffe S et al (2011) A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex((R)) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 18:1122–1131CrossRefPubMedGoogle Scholar
  26. 26.
    Wade DT, Collin C, Stott C et al (2010) Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult Scler 16:707–714CrossRefPubMedGoogle Scholar
  27. 27.
    Russo M, Calabro RS, Naro A et al (2015) Sativex in the management of multiple sclerosis-related spasticity: role of the corticospinal modulation. Neural Plast 2015(656582):2015–2029.  https://doi.org/10.1155/2015/656582 Google Scholar
  28. 28.
    Patti F, Messina S, Solaro C et al (2016) Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. J Neurol Neurosurg Psychiatry 87:944–951CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Zettl UK, Rommer P, Hipp P et al (2016) Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis. Ther Adv Neurol Disord 9:9–30CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Coghe G, Pau M, Corona F et al (2015) Walking improvements with nabiximols in patients with multiple sclerosis. J Neurol 262:2472–2477CrossRefPubMedGoogle Scholar
  31. 31.
    Flachenecker P, Henze T, Zettl UK (2014) Long-term effectiveness and safety of nabiximols (tetrahydrocannabinol/cannabidiol oromucosal spray) in clinical practice. Eur Neurol 72:95–102CrossRefPubMedGoogle Scholar
  32. 32.
    Koehler J, Feneberg W, Meier M et al (2014) Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticity. Int J Neurosci 124:652–656CrossRefPubMedGoogle Scholar
  33. 33.
    Paolicelli D, Direnzo V, Manni A et al (2016) Long-term data of efficacy, safety, and tolerability in a real-life setting of THC/CBD oromucosal spray-treated multiple sclerosis patients. J Clin Pharmacol 56:845–851CrossRefPubMedGoogle Scholar
  34. 34.
    Trojano MTHC (2016) CBD observational study data: evolution of resistant MS spasticity and associated symptoms. Eur Neurol 75(Suppl 1):4–8CrossRefPubMedGoogle Scholar
  35. 35.
    Goodman AD, Brown TR, Edwards KR et al (2010) A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 68:494–502CrossRefPubMedGoogle Scholar
  36. 36.
    Zorner B, Filli L, Reuter K et al (2016) Prolonged-release fampridine in multiple sclerosis: improved ambulation effected by changes in walking pattern. Mult Scler 22:1463–1475CrossRefPubMedGoogle Scholar
  37. 37.
    Egeberg MD, Oh CY, Bainbridge JL (2012) Clinical overview of dalfampridine: an agent with a novel mechanism of action to help with gait disturbances. Clin Ther 34:2185–2194CrossRefPubMedGoogle Scholar
  38. 38.
    Orsnes GB, Sorensen PS, Larsen TK et al (2000) Effect of baclofen on gait in spastic MS patients. Acta Neurol Scand 101:244–248CrossRefPubMedGoogle Scholar
  39. 39.
    Giovannelli M, Borriello G, Castri P et al (2007) Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spasticity in patients with multiple sclerosis. Clin Rehabil 21:331–337CrossRefPubMedGoogle Scholar
  40. 40.
    Ochs G (1995) Die Behandlung der schweren Spastizität. Thieme, StuttgartGoogle Scholar
  41. 41.
    Smail BD, Peskine A, Roche N et al (2006) Intrathecal baclofen for treatment of spasticity of multiple sclerosis patients. Mult Scler 12:101–103CrossRefPubMedGoogle Scholar
  42. 42.
    Rekand T, Gronning M (2011) Treatment of spasticity related to multiple sclerosis with intrathecal baclofen: a long-term follow-up. J Rehabil Med 43:511–514CrossRefPubMedGoogle Scholar
  43. 43.
    Rommer PS, Kamin F, Abu-Mugheisib M et al (2016) Long-term effects of repeated cycles of Intrathecal triamcinolone acetonide on spasticity in MS patients. CNS Neurosci Ther 22:74–79CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH 2017

Authors and Affiliations

  • T. Henze
    • 1
    Email author
  • W. Feneberg
    • 3
  • P. Flachenecker
    • 4
  • D. Seidel
    • 5
  • H. Albrecht
    • 6
  • M. Starck
    • 3
  • S. G. Meuth
    • 2
  1. 1.Praxisgemeinschaft für Neurologie, Psychiatrie, PsychotherapieRegensburgDeutschland
  2. 2.Department für Neurologie und Institut für Translationale NeurologieKlinik für Allgemeine Neurologie, UniversitätsklinikumMünsterDeutschland
  3. 3.Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke gemeinnützige GmbHBergDeutschland
  4. 4.Neurologisches Rehabilitationszentrum QuellenhofBad WildbadDeutschland
  5. 5.BocholtDeutschland
  6. 6.Praxis für NeurologieMünchenDeutschland

Personalised recommendations